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Summary (200 words) 
Leptomeningeal malignancy (LM) complicates childhood cancers including 
leukaemias, brain tumours and solid tumours.  In leukaemia it is assumed that the 
malignancy invades the leptomeninges via the vascular route.  In brain tumours 
dissemination from the primary tumour, before or after surgery via the CSF 
pathways is assumed.  However, there is evidence to support the vascular route of 
dissemination. Success in treating LM represents a rate-limiting step to cure, 
which has been successfully overcome in leukaemia with intensified systemic, 
combined with intra-CSF therapy, replacing cranial radiotherapy for the majority.  
This de-escalated CNS directed therapy is still associated with a degree of 
neurotoxicity.  This balanced benefit justifies exploration of ways to further de-
escalate CNS directed therapy. In primary brain tumours standard therapy rely 
upon cranio-spinal radiotherapy with the attendant risk of acute and delayed brain 
injury and endocrine deficiencies compounding post radiation impairment of 
spinal growth.  Alternative ways of treating the lepto-meninges by intensifying 
drug therapy delivered to the CSF are under investigation.  Preliminary evidence 
suggests improved outcomes. 
This review seeks to describe the methods of intra-CSF drug delivery, the current 
drugs in use and consider how the technique may be modified and additional 
drugs might be selected for this route of administration.   
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Key Messages   
• Cancer affects 1:300 young people by age 20, <60% of whom have 
leptomeningeal involvement. 
• In leukaemias, CNS directed therapy without cranial radiotherapy, has 
been successful in treating leptomeninges with reduced brain and 
endocrine consequences for survivors, further de-escalation of CNS 
directed therapy  is being considered 
• In brain tumours, cranio-spinal radiotherapy is effective but extremely 
toxic.  Intensifying drug therapy with intra-CSF drug delivery is being 
explored with promising results. 
• Intra-CSF drug delivery in brain tumours is complicated by post-operative 
changes and the co-existence of ventricular peritoneal shunts. 
• Exploring alternative ways of delivering intra-CSF drugs and expanding 
the range of drug suitable for this purpose are necessary to allow the 
potential benefits to be offered to all. 
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Background 
Cancer affects 1:300 people by aged 2 years, at least two-thirds of whom present 
a risk of leptomeningeal involvement (LMI) [Charles Stiller, Personal 
Communication].  When it occurs, it is a rate-limiting step for cure thereby 
presenting a challenge to the therapist especially in primary brain tumours where 
the risk of LMI is greatest. Historically, craniospinal radiotherapy has been the 
standard approach to treating the risk of, and actual LMI, complicating brain 
tumours. Indeed, it offered the first examples of “cure” in medulloblastoma (1,2) . 
 
Aggressive pre-emptive treatment of LMI has been a routine component of 
treatment for childhood leukaemias and high-grade lymphomas since the 1970s 
and is considered essential for cure. Initial use of central nervous system (CNS) 
targeted radiotherapy was associated with unacceptable long-term cognitive and 
adverse endocrine effects leading to gradual phasing out of its routine use in first-
line therapy.  It has largely been replaced with intensified systemic and intra-
cerebrospinal fluid (CSF) therapies.  Despite this, CNS-directed therapy remains 
potentially toxic, with a lack of reliable biomarkers to guide risk-adapted 
therapies. Thus, the challenge in haematological malignancies is reducing the 
toxicity of CSF-delivered drug regimens in first line treatment without 
compromising efficacy. 
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Risks of radiation therapy to the brain 
Extended fields of high dose radiotherapy early in life carry heavy penalties for 
brain development, affecting the development of normal cognition and memory, 
limiting spinal growth and damaging endocrine function (particularly growth 
hormone).  The risk of second malignant and benign brain tumours is particularly 
worrying in disease groups where cure rates now exceed 70% at 5 years and 
beyond.  Scatter dose radiation to non-CNS tissues in the neck, thorax and 
abdomen increase the volumes of tissue at risk of second tumour development 
after radiation damage.  These penalties are greatest when used in the youngest 
children with the most tissue development and growth to follow (3). The 
modification of radiation fields using Intensity-Modulated Radiation therapy 
(IMRT), tomo-therapy and proton therapy offer reductions in scatter dose 
radiation and greater precision of tumour bed volumes but cannot compensate for 
the radiation brain injury within boosted fields, consequent upon cranio-spinal 
radiotherapy (3,4).   The balance of benefits and risks therefore have been 
difficult to judge in primary brain tumours, in contrast to leukaemia and 
lymphoma, because the brain needs to be treated vigorously to eradicate the 
primary tumour with surgery, radiotherapy and possibility of safely reducing the 
risk of radiation brain injury.    Progress has been slow in clinical trials because of 
the diverse primary brain tumour groups, where optimizing curative therapy in 
high risk disease was initially prioritized in trial design; subsequently, trials were 
directed at de-escalating radiation dosing and field volumes by introducing 
7 
clinical and molecular risk stratification and compensatory systemic 
chemotherapy (4).   
 
CSF therapy in Brain Tumours 
A recent trial has identified that CSF etoposide (0.25-1mg) given to children and 
young adults with malignant brain tumours can be combined safely with systemic 
chemotherapy and radiotherapy using daily or twice daily bolus administration 
over 5-10 days every 2-5 weeks (5)(Ref). There have also been reports of the use 
of intra-ventricular methotrexate in patients with metastatic, relapsed or refractory 
medulloblastoma, which was well tolerated.  A meta-analysis identified a 
correlation between cumulative intra-ventricular methotrexate dosing and 
improved outcome (6,7).  A single arm study in highly malignant atypical teratoid 
rhabdoid tumours (ATRT) included the use of intra-CSF Cytarabine, methotrexate 
and hydrocortisone (8) and another is testing intra-CSF Etoposide and Topotecan/ 
Depocyte® as part of an anti-angiogenic multi-agent regime in relapsed 
medulloblastoma (8,9). A meta-analysis of intra-ventricular therapy found that 
intra-ventricular therapy contributed to enhanced survival in Atypical Teratoid 
Rhabdoid Tumour (ATRT) (10).  An international randomized trial investigating 
the role of CSF delivered methotrexate, in pre-school age children with low risk 
medulloblastoma was about to be launched but is being reconsidered as a result of 
the early closure of ACNS 1221 trial (11), which excluded ventricular therapy 
from the regimen demonstrating an excess of relapses compared to a similar 
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chemotherapy study including intra-ventricular methotrexate.  The SHH 
biological sub-group in this trial had favourable outcomes and the role of different 
adjuvant strategies are currently being considered for randomized comparisons 
where intra-ventricular therapy may be part of the strategy selection (12,13).   
There is growing evidence therefore that intra-ventricular therapy with the 
historical drug methotrexate and other drugs can contribute to enhanced outcomes 
in higher risk malignant tumours types. 
 
Novel methods of CSF drug formulation, delivery or scheduling have not been 
explored.  Possible restraining factors include the rarity of the clinical problem in 
children compared to adults, where 1:2 people are at risk of cancer and 40% are at 
risk of LMI.  There is also a need to test new systems in children, and the added 
cost and challenge of international collaboration and pharmaceutical engagement. 
The scene is set therefore for further investigation of CSF delivered therapy in 
primary brain tumours, to both enhance tumour control and reduce neurotoxicity 
in risk-adapted therapies  
 
In this review, we will re-consider the potential for CSF delivered drug therapies 
in childhood malignancies and discuss how optimization of CSF drug delivery 
might be explored in future trials of both CNS and haematological malignancies. 
We will consider haematological malignancies first, as the most progress has been 
made with these to date. 
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Leptomeningeal infiltration in haematological malignancies  
LMI complicating haematological malignancies is a diffuse and/or multifocal 
invasion of the leptomeninges at the vascular-meningeal interface (14).  
Leukaemic blasts are thought to reach the leptomeninges by the vascular route, 
crossing the blood-CSF barrier, or by direct extension along bridging veins from 
the adjacent skull and vertebral bone marrow (figure 1) (15,16).  
 
 
 
Several lines of evidence suggest that LMI in ALL is significantly 
underdiagnosed using conventional cyto-morphology (cytospin) and is likely to 
be present in most children at initial diagnosis (16–18).  Indeed, the introduction 
of universal CNS-directed therapy, irrespective of initial cytospin findings, led to 
a dramatic improvement in overall survival (OS) from 20-30% to 50-60% in the 
1970’s (19). Initially radiotherapy was used to treat LMI but high rates of 
secondary CNS malignancies and endocrinopathies led to a switch to targeted 
treatment with intensified methotrexate or triple intrathecal therapy (methotrexate, 
cytarabine and steroids), alongside systemic drugs with good CNS penetration. 
This approach has reduced CNS relapse to less than 5% and increased OS rates 
>90% (20). However significant methotrexate-related neurotoxicity still occurs. 
Acute neurotoxicity includes headaches, somnolence, seizures, or methotrexate 
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“stroke-like syndrome” (19). In addition, methotrexate has been implicated as one 
of the causative agents for  chronic neurocognitive defects seen in up to 50% of 
children post ALL therapy ((21,22)). Efforts are now concentrating on reducing 
the burden of CNS-directed therapy by improved systemic control, and more 
sophisticated methods to monitor the response of LMI to the delivered therapies 
to allow tailoring of treatment intensity to a child’s individual risk of CNS 
relapse. Refractory and/or relapsed CNS leukaemia can be very challenging to 
treat and novel agents with a reduced toxicity profile for these heavily pre-treated 
patients would be advantageous. These include liposomal cytarabine and 
immunotherapies such as CAR-T cells and bi-specific antibodies. 
 
Leptomeningeal infiltration in primary brain and other solid tumours 
LMI has a similar pathological appearance in primary brain malignancies.  In 
medulloblastoma, the commonest childhood malignant brain tumour, 30% present 
with LMI (23) and 60% have LMI at relapse (24).  All are treated assuming LMI 
is a risk. A recent study by Zapotocky et al. has however suggested that group 3 
tumours tend to show laminar (diffuse) metastatic dissemination, group 4 tumours 
show a mixture of laminar and focal metastases and sonic hedgehog tumours are 
associated with multifocal lesions. Thus, the pattern of metastasis appears to be 
linked to the underlying molecular drivers of the disease and may also link to 
outcome (25). LM disease has been found to differ in its molecular profile from 
the primary tumour suggesting clonal selection as part of process of dissemination 
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(4,26–28). Thus, metastatic tumours have either diverged prior to treatment or 
been selected and expanded as a result of treatment. In either case, the resultant 
leptomeningeal metastasis has genetically diverged and is unlikely to respond to 
same targeted treatment as the tumour of origin. Leptomeningeal dissemination 
has traditionally been hypothesized to be via the CSF whereby cells enter the CSF 
at the tumour : CSF interface or after surgical disruption during tumour 
resections.  Recent evidence has, however, identified that there may be a 
proportion of cases where tumour cells reach the LM via the vascular route as in 
leukaemia / lymphoma (29,30).  These alternatives routes of dissemination to LM 
would justify the use of both systemic and CSF delivered drugs in their 
prevention and treatment. Although not necessarily the same targeted drug since 
both may have evolved. 
 
Treatment Considerations 
Cytotoxic concentrations in the CSF of systemically administered drugs are 
compromised by the blood-brain-barrier and blood-CSF barrier. Drug transfer 
from blood to CSF is compromised by tight junctions between the capillary 
endothelial cells (31,32).  This barrier can be overcome by choosing drugs with 
specific physical and pharmacological characteristics including: low molecular 
weight (<500 kDa), high lipid solubility (33), structures with few nitrogen and 
oxygen atoms (preferably <8-10), small physical size <11 nm, low protein 
binding and hydrogen bonding (33). Drug penetration of CSF is also inhibited by 
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drug influx and efflux transporters, increased interstitial pressure of brain and 
tumour and reduced blood flow in the tumour (34).  Intra- and extracellular 
enzymes may inactivate or be required to activate compounds.  
 
One approach to this poor penetration of drugs into the CSF is to use exceptional 
systemic dosing such as high dose methotrexate with folinic acid rescue in 
leukaemias (35) or high dose multi-agent chemotherapy with stem cell rescue in 
brain tumours (36) to try and achieve higher concentrations of cytotoxic drugs 
within the CNS. Alternatively, intra-CSF administration is a method to 
circumvent these barriers, as was observed in a study in brain tumour patients 
where systemic HD-etoposide (400 mg/m2 over 96 hours) was administered as 
part of intensified systemic therapy.  This schedule failed to achieve a cytotoxic 
CSF concentration (>0.1 µg/ml) (37), whilst the same drug Etoposide 
administered into CSF at 0.5 mg daily for 5 days achieved a CSF concentrations 
at more than 100-fold the level achieved by systemic administration with 
negligible systemic or CNS toxicity.  
 
The successful use of intra-CSF therapy in childhood leukaemia / lymphoma is 
notable.  Although the choice of agents that are suitable for intra-CSF delivery 
and also effective against leukaemia has severely limited the selection of drugs for 
testing in primary brain tumour indications,  The only new drug in the past four 
decades developed for this route of administration is liposomal cytarabine 
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(Depocyte®).  On the one hand, it has an attractive pharmaceutical profile 
because of its sustained release pattern reducing the need for repeated lumbar 
puncture; on the other hand, arachnoiditis side effects requiring concomitant 
steroids, coupled with its high cost and complex manufacturing process has 
resulted in its recent withdrawal from the market (38).  
 
The lack of new drug development has led researchers to explore existing 
chemotherapy agent’s suitability for administration via the CSF, mainly off 
license. Their selection being justified by pharmacological principles and 
published evidence. Shortlists of existing agents have been drawn up for primary 
brain tumours and preliminary trials of their use have been reported (39).  A key 
feature has been to select drugs with no evidence of neurotoxicity, as direct 
administration to the CSF will bring the drug into direct contact with brain at CNS 
concentrations exceeding that achieved by systemic routes.  Using this approach, 
methotrexate was excluded as a suitable candidate because of the extensive 
evidence of its neurotoxicity especially in previously irradiated patients.  A UK 
national guideline has specified intra-CSF methotrexate in favourable risk 
medulloblastoma in pre-school age children (13,40).  Neurotoxicity of this 
approach is, therefore, anticipated but may be difficult to attribute to the drug as 
opposed to the toxicity of delayed diagnosis, surgical interventions and systemic 
chemotherapy (41).  This could be the focus of future randomized trials. 
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Optimising LM-directed drug therapy   
The requirements for LM-directed therapy are: maintaining an optimized 
therapeutic concentration at the tumour site, with acceptable systemic and 
neurotoxicity (42) to eradicate tumour cells in order to stabilise tumour-related 
neurological signs, while maintaining quality of life and, where highly effective, 
prolonging survival (43). 
 
To optimize intra-CSF chemotherapy efficacy, CSF flow characteristics and drug 
pharmacokinetics need to be taken into account.   
 
 
CSF distribution volume is static in children over 3 years of age at 110-150 ml 
(44). Intraparenchymal penetration of intra-CSF administered drugs is limited to 
2-3 mm (45). Characteristics favouring CSF drug delivery include direct contact 
with tumour cells, small CSF volume of distribution and the absence of a first 
pass effect.  This allows very low drug dosages to achieve cytotoxic levels in the 
CSF, thereby avoiding systemic toxicity.   
 
CSF velocity, and therefore speed of mixing and dissemination of drug 
administered to CSF spaces, is determined by the choroid plexus flow.  This is 
amplified by a pulsatile CSF motion (caused by blood flow and breathing pattern) 
(46) at an average of 0.35 mL/min (34), occupying the entire CSF space in 5-7 
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hours (47), thus exchanging the entire CSF volume four times a day. This is 
referred to as bulk flow.  The clearance rate limits drug-to-tumour exposure time, 
which theoretically could compromise the efficacy of cell-cycle dependent drugs 
such as MTX, etoposide and cytarabine. Solid tumours have slower proliferation 
rates where prolongation of contact between drug and tumour would be 
theoretically advantageous.  
 
Where physiological CSF flow is from choroid plexus in lateral, third and fourth 
ventricles to the arachnoid granulations in the superior sagittal sinus, the most 
efficient administration route is by intra-ventricular route with the drug flowing 
with the CSF bulk flow. This route of administration requires an intraventricular 
catheter such as an Ommaya reservoir. This is an implantable device consisting of 
a small capsule situated between the skull and overlying scalp connected to a 
catheter communicating directly with one of the lateral ventricles (48–50).  
 
This permits painless access to the ventricular CSF for both sampling and drug 
administration.  Infection can be controlled, but not excluded, by meticulous 
aseptic technique.  Case selection requires a clear understanding of CSF flow 
patterns around the CSF spaces.  This has been compared favourably to the 
intralumbar route in studies with MTX (51), mafosfamide (52) spartaject busulfan 
(53), and topotecan (54,55). Furthermore, lumbar injections are often 
unknowingly misplaced leading to ineffective delivery to the CSF (56).  It has 
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been demonstrated that lying flat after lumbar puncture optimizes drug 
distribution to upper half of the spinal cord.  Intensification of lumbar 
administration by daily delivery is used but unpopular because of local discomfort 
with repeated lumbar puncture and, in children, the requirement for sedation or 
anaesthesia (19). 
 
It has been hypothesized that the pharmacokinetics of the drug delivery to CSF 
would be best optimized by continuous infusion as opposed to bolus 
administration (34). A bolus administration achieves a peak concentration, 
followed by washout by CSF bulk flow over time. A continuous infusion would 
reach a plateau drug concentration throughout CSF spaces. Such an approach 
requires an administration device offering stable prolonged intra-CSF drug access 
with a portable continuous infusion pump (34) suitable for children of all ages 
(57).  In post-operative states additional consideration needs to be given to the 
impact of raised intra-cranial pressure, meningitis or proteinaceous CSF 
interacting with CSF concentration and circulation / distribution of intra-CSF drug 
(58). 
 
Despite these considerations, the standard approach to intra-CSF drug 
administration for leukaemia lymphoma is intermittent lumbar injection 
frequently under anaesthesia.  The frequency of administration is intensified 
where frank CNS disease is seen on CSF sampling.  Standard protocols deliver 
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intra-CSF therapy at weekly to monthly or 3-monthly intervals.  The efficacy of 
such intervals coupled with the brief presence of the drug in the CSF due to its 
removal by bulk flow has not been studied pharmacologically to justify this 
approach.  Its introduction, in combination with intensified systemic therapy to 
replace more damaging CNS radiation, justified the empirical adjustment to 
protocols (59). Multi-centre clinical trials concluded that sustained use of intra-
CSF therapy without cranial radiotherapy offered acceptable CNS- relapse rates 
(60–62).    Intrathecal therapy offers much lower rates of neuroendocrine 
problems and secondary tumours than craniospinal irradiation. However, 
prolonged intra-CSF methotrexate and/or triple therapy has been associated with 
adverse neurocognitive and neurobehavioural outcomes (63) and concerns are 
emerging about possible “accelerated aging” in the CNS 20-30 years post therapy 
(64).  
 
The use of intraventricular (Ommaya reservoir) delivery of CNS-directed therapy 
in childhood ALL has declined over the years despite early literature , mainly 
from the 1970’s, reporting superior pharmacokinetics, its ease of use, and possibly 
increased efficacy compared to conventional lumbar delivery (65) (64). It should 
be noted that no randomised controlled trial of intrathecal vs intraventricular 
therapy has ever been performed in ALL and the literature consists of small 
mixed case series mainly from the 1970’s and 1980’s (56). The decline in use of 
Ommaya reservoirs may have been due to concerns about its usual placement for 
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life and the risks of CNS infection, although meticulous neurosurgical and aseptic 
technique has reduced these risks considerably (56,66,67).  
 
Hydrocephalus / Ventricular shunting 
For these reasons, we propose that protracted CSF infusions monitored by CSF 
sampling of drug concentration would be a preferable strategy in patients with 
shunts, a stable CSF drug concentration may be achieved allowing equilibration 
across the CSF spaces as long as there are no isolated cavities (figure 2).   Where 
even distribution cannot be guaranteed, CSF flow studies prior to intra-CSF drug 
administration with either 111Indium-diethylenetriamine penta-acetic acid, 99Tc 
macro-aggregated albumin, or gadolinium (47,68–70) may be warranted, since 
standard MRI imaging might be insufficiently sensitive to assess flow 
characteristics in detail (69). Surgical intervention in adults has been proposed to 
remove bulky disease and restore CSF flow, which has been shown to prolong 
survival, lower treatment related morbidity and death rate from LMI (68,71,72)  
We are unaware of such surgical interventions being adopted in children.   
 
Drug selection for intra-CSF delivery 
Methotrexate is the most commonly used intra-CSF chemotherapy agent. This is 
largely due to its position as one of the first effective therapies for leukaemia in 
the 1950’s and 1960’s, rather than a critical evaluation of potential efficacy and 
toxicity profiles of a variety of alternative intra-CSF agents. In fact, using modern 
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criteria, the neurotoxicity profile of methotrexate makes it an unattractive first 
choice agent for intra-CSF delivery.  Despite this, it has repeatedly been shown in 
large scale RCTs to be an effective drug for prevention of CNS relapse (60–
62,73) and therefore remains widely used in ALL and lymphoma protocols (19).  
 
Since intra-CSF therapy for brain tumours is in its infancy, there is a great 
opportunity to move away from methotrexate to alternative less toxic intra-CSF 
agents. Conroy et al (39) defined a number of required drug properties for intra-
CSF administration: 
1. Clinical property: 
• Non-irritant 
• Neurotoxicity low or absent 
• Evidence of tumour sensitivity 
2. Biological property: 
• CSF transport system absent 
• Cell cycle non-specific drugs 
3. Physiochemical and pharmaceutical properties: 
● Active in CSF 
● Hydrophilic and/or ionised at CSF pH therefore low membrane 
permeability (to minimise diffusion out of CSF) 
● Molecular size (>700 kDa) 
● Suitable formulation readily available 
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Taking these characteristics into account Depocyte® (liposomal cytarabine, slow 
release formulation), mafosfamide (cyclophosphamide analogue), and etoposide 
were selected as suitable candidates for intra-CSF treatments suitable for trial in 
medulloblastoma (panel). Depocyte® and mafosfamide can cause chemical 
arachnoiditis (fever, nausea, vomiting, headache, and back pain) (74,75), 
justifying concomitant dexamethasone (0.15 mg/kg/dose IV or orally, twice a day 
for 5 days) (76–78), or low infusion rate (maximum 1 ml/min) (52).  However, 
they have both now been withdrawn from production and are unavailable (38).  
Depocyte® was withdrawn due to production difficulties, whilst Mafosfamide 
was never fully registered as a drug and its manufacture was discontinued. 
 
Other complications are transient such as headaches (37,43,74,79), infections of 
intra-CSF administration devices in <10% of patients (37,43,74,80), nausea and 
vomiting, seizures, and confusion (79,80). Symptomatic subacute 
leukoencephalopathy (confusion, somnolence or irritability, ataxia, dementia and 
tremor or myelopathy are rare events (37,43,79), and are more common with 
concurrent systemic treatment and/or radiotherapy (81–85), or CSF flow 
obstruction (68,69), 
 
Use of systemic immunotherapies to target leptomeningeal infiltration 
Recent advances in immunotherapies have opened up new treatment approaches 
for relapsed/refractory LMI in ALL. Systemically delivered chimeric antigen 
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receptor T cells (CAR-T cells) have been shown to home to the CNS and produce 
long-term remissions in patients with CNS-relapses (86). Indeed, excellent CAR-
T cell expansion has been demonstrated in CSF following IV administration (87). 
Novel bi-specific antibodies, such as Blinatumomab (88), also have proven 
efficacy against CNS leukaemia. It is worth noting that these therapies are also 
associated with significant neurotoxicity although the exact mechanisms of this, 
and whether they relate to the presence of LMI or systemic cytokine release, 
remains unproven (89,90). In addition, other barriers to widespread adoption of 
immunotherapy for LMI in ALL are large treatment costs and the current lack of 
effective agents against T-ALL (which has higher rates of refractory LMI than B-
ALL). 
 
When evaluating new products, the degree of CNS-homing of different classes of 
immunotherapy should be taken into account. In contrast, to CAR-T and 
bispecific antibodies, NK-based therapies (91) and monoclonal antibodies such as 
Rituximab may not be able to cross into the CSF without direct intra-CSF 
delivery (92).  
 
The application of immune strategies in brain tumours is in early development 
preliminary experience is limited to exploration of the use of intrathecally 
delivered immune-stimulants such as Interleukin 2 and interferon beta (93).   
Intraventricular administration of radio-immunotherapy using (131) I-3F8 in 
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medulloblastoma has been shown to be safe and feasible and could be used to 
complement other therapies in the future (94). 
 
Future directions for treatment of LMI 
Haematological malignancies 
Interestingly, the use of intra-CSF therapy for haematological malignancies and 
brain tumours appear to be going in opposite directions.  In haematological 
malignancies, the focus is on optimising the use of systemic drugs with good CSF 
penetration and concomitantly reducing the burden, and, potentially, the toxicity 
of intra-CSF therapy.  Whereas in brain tumours, judicious use of CSF directed 
therapy for LMI is gaining importance with an associated focus on other CNS 
directed drug delivery techniques to try to enhance efficacy of drug therapy for 
primary brain tumours.  
 
Despite this, many opportunities for advances in treatment of LMI in ALL exist.  
Firstly, sensitive biomarkers need to be developed to allow accurate detection of 
LMI and to track its response to initial CNS-directed therapy. Once available, 
future studies would be able to use these biomarkers to test de-escalation of CNS 
directed therapy for patients at low risk of CNS relapse, thus significantly 
reducing their exposure to currently used neurotoxic agents. A move away from 
methotrexate to either less neurotoxic cytotoxic agents such as cytarabine, 
etoposide, topotecan or carboplatin, or newer targeted, non-neurotoxic treatments 
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for intra-CSF delivery would benefit all patients, but the immense difficulties in 
switching from an efficacious (albeit toxic) agent to an unproven novel agent are 
not to be underestimated.  
 
Advances in this area are likely to be seen by testing existing previously unused 
agents via the intra-CSF route as well as novel agents, as bolus or infusional 
therapy, in cases of relapsed or refractory disease. The point of drug delivery may 
need to be reconsidered.  Although, systemic immunotherapy may prove to be the 
first-line choice in leukaemias it will be limited by cost, toxicity and lack of 
efficacy against T-ALL. 
 
CNS malignancies 
In brain tumours, taking the lead from haematological malignancies, the priority 
is to sustain control of LM disease whilst reducing the burden of morbidity and 
late consequences particularly of radiation therapy to the cranio-spinal axis.  One 
way this could be achieved would be to establish devices and techniques to 
deliver infusional intra-CSF therapy and explore the most suitable existing and 
new agents emerging from research and development for this route of 
administration.  Ninety percent of new cancer drugs do not cross the blood brain 
barrier sufficiently for an effect to be anticipated by systemic administration. Such 
drugs delivered directly to the CSF may have a much greater impact.  Their 
exploration in trials via the intra-CSF route should be prioritized involving 
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children with specific requirement to avoid the serious neuro-toxicity of cranio-
spinal radiotherapy in pre-school age children and in children with relapsed 
disease initially, once feasibility of intra-CSF administration is established. 
 
Priorities for future research 
Perhaps the most important developments is a commitment to identify new 
effective and less toxic drugs, and safe and easy systems for their delivery, to 
target malignancies in the LMI. The proposed infusional intra-CSF studies are 
being pursued with the intent of developing a platform for their testing and 
selection of drugs for further development.  Sustained release systems such as 
Depocyte® offered a sustained profile after a single injection.  An expanded range 
of such preparations with targeted agents is an attractive prospect.  Sharing 
delivery systems and target selection with the needs of adult practice would create 
synergy for their commercial development. 
 
Search strategy and selection criteria 
Relevant literature was identified using PubMed and article reference lists. Search 
terms comprised leptomeningeal, paediatric, adolescent, cancer, leukaemia, brain 
tumour, medulloblastoma, cerebrospinal fluid and drug-delivery. Search was 
restricted to English language with no date restrictions  
 
Author contribution: 
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Figure 1:  Mechanisms of leptomeningeal dissemination from primary brain 
tumors via CSF or haematogenous routes  
Adapted from ref 29.  [Note: this is from Cell (published by Elsevier) and open 
access, so no need to ask for permission. We will remove the mouse 
and change the adult to a child]   
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Figure 2:  Routes of administration for intra-CSF therapy (VR - ventricular route; 
LR – lumbar route).  LR can be used in patients with ventriculoperitoneal shunts 
 
 
Panel:	 Drugs	 graded	 by	 eligibility	 for	 trial	 by	 intrathecal	
administration	for	medulloblastoma	(ref	37	-	Conroy	et	al	2010)	
	
	Agents	under	trial	
Liposomal	cytarabine	(Depocyte®)*	
Mafosfamide*	
	
Agents	suitable	for	clinical	trial	
Carboplatin	
Etoposide	
Blue	is	cerebrospinal	fluid	space 
Red	is	blood	space	 
VR:	ventricular	route	 
Through	Ommaya	reservoir 
LR:	lumbar	route	 
Through	Port-A-Cath	with	
lumbar	line	extension 
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Nimustine	(ACNU)	
		
Drugs	requiring	further	investigation	before	clinical	trial	
Floxuridine	(FDUrd)	
4-hydroperoxy-cyclophosphamide	
	
Drugs	requiring	further	investigation,	lower	priority	
Diaziquone	
Mercaptopurine	
Rubitecan	
Topotecan	
Radio-immunotherapy	131I-3F8	murine	monoclonal	antibody	
	
Drug	with	insufficient	information	to	grade	
Temozolomide	
	
*	 This	 drug	 has	 now	 been	 withdrawn	 from	 production	 by	 the	
manufacturer	
 
